HALOZYME THERAPEUTICS, INC.

Halozyme's business is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme, rHuPH20. The company's development pipeline is concentrated in clinical stage and pre-clinical stage oncology products, including its proprietary investigational drug, PEGPH20, a pegylated version of rHuPH20, which targets hyaluronan (HA) high tumors. The company is in various phases of clinical trials with PEGPH20 across multiple solid tumor types, including pancreatic cancer, non-small cell lung cancer (NSCLC), and gastric cancer, to test the drug's safety and efficacy. Halozyme has one FDA approved product (Hylenex recombinant, hyaluronidase human injection ). The company also licenses its drug delivery technology Enhanze to other biopharmaceutical companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Bristol Myers Squibb and Lilly.